Phase I and II Study Of Stereotactic Body Radiotherapy in Medically Unresectable Patients With Stage 1 NSCLC
The most common treatment for early stage lung cancers is to remove the cancer with surgery.
Patients with serious underlying health problems like emphysema, diabetes, or heart disease
who develop an early stage lung cancer may not be eligible for the standard surgical
treatment. The most common alternative to surgery is conventional radiation treatment
called fractionated radiotherapy. "Fractionated radiotherapy" means several weeks of
treatment with daily radiation sessions. While this treatment is sometimes successful at
killing the cancer, it is not as effective as surgery and may significantly damage the
surrounding lung tissue.
Newer treatments using radiotherapy have been developed and used for patients with
metastases (spreading cancer) to the lungs. Stereotactic radiotherapy uses a frame to guide
highly focused beams of radiation at the cancer while avoiding the normal surrounding
tissue. Stereotactic radiotherapy also uses a higher daily dose of radiation. The higher
daily dose may be more effective than conventional radiotherapy at killing cancer cells and
may also decrease side effects.
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
The purposes of this research study are (1) to find the highest dose of stereotactic radiotherapy that can safely be used for treatment of early stage non-small cell lung cancer.
5 years from enrollment completion
Ronald McGarry, MD
Indiana University - Department of Radiation Oncology
United States: Food and Drug Administration
|Indiana University, Department of Radiation Oncology||Indianapolis, Indiana 46202|